THX Pharma and Biocodex have entered a strategic licensing agreement covering three rare diseases, with Biocodex acquiring rights to develop and commercialise two drug candidates across multiple territories. The deal is valued at up to €173 million, including a €12 million upfront payment, milestone payments and tiered double‑digit royalties.
The agreement grants Biocodex a global exclusive licence for Batten-1, developed by THX Pharma for juvenile Batten disease, and a regional exclusive licence for TX01 in the United States and Canada for the treatment of Gaucher disease and Niemann‑Pick disease type C.
These genetically inherited conditions, many of which affect children, lead to severe and progressive visceral, haematological or neurological impairments. With limited or no therapeutic options available, both companies describe the programmes as significant scientific and medical advances.
Under the partnership, THX Pharma will lead clinical development with financial and scientific support from Biocodex. Biocodex will oversee compassionate use, market access and commercial activities in the licensed territories.
Mathieu Charvériat, President and Chief Executive Officer of THX Pharma, said: “This strategic agreement with Biocodex represents a major step forward and a significant value-creation milestone for THX Pharma. It validates the scientific and strategic value of our assets by partnering with a leading French pharmaceutical company with strong clinical development capabilities, recognized industrial and regulatory expertise, and a solid international commercial presence in the field of rare neurological diseases.”
He added that the alliance would enable a more ambitious project in Europe and the United States, “thereby maximizing our chances of success for the benefit of patients”.
Nicolas Coudurier, Chief Executive Officer of Biocodex, explained: “By partnering with THX Pharma, Biocodex is fully aligned with its innovation strategy dedicated to rare diseases with high unmet medical needs.”
He said the company was convinced by THX Pharma’s scientific expertise and its alignment with Biocodex’s values, adding that the collaboration would continue its work with organisations such as the Beyond Batten Disease Foundation.
